Form 4 for SYRE Spyre Therapeutics, Inc.
Accepted 2024-11-08 00:00:00 ET · period of report 2024-11-06 · accession 0001636282-24-000089 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-11-08 | 2024-11-06 | SYRE | Albers Jeffrey W. | Dir | S - Sale | $36.76 | -6,700 | 27.4K | -20% | -$246.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-06 | S | D | 6,700 | $36.76 | 27,360 | I By Sessions LLC | — | — | (F2) The price reported is a weighted average sale price of the Common Stock. These shares were sold in multiple transactions at prices ranging from $36.48 to $37.00, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |